Refine by
Colitis Articles & Analysis
30 news found
Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by suppressing the immune system and reducing inflammation in the body. ...
Biopsy samples of inflamed colonic mucosa from patients and mice with colitis released opioids that activated DOPr on nociceptors to cause a sustained decrease in excitability. ...
Walid joined the company in early 2017 and led it through a critical and transformative phase, including the successful completion of the Phase 3 studies of filgotinib in rheumatoid arthritis and ulcerative colitis. We recognize his important contribution to building out the development organization and to bringing our company to the fully integrated biotech that we are today. ...
“It is comforting to see that we still have the option for a benefit-oriented use of filgotinib in ulcerative colitis to provide fast anti-inflammatory efficacy to the main patient ...
Commercial progress Since becoming European marketing authorization holder (MAH) of Jyseleca®, we successfully set up our own commercial capabilities and are currently operational throughout Europe in the current approved indications RA and ulcerative colitis (UC). The financial results for the third quarter of 2022 show continued strong sales momentum for Jyseleca®, and ...
Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland Article ...
The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com. ...
The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com. ...
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. ...
Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in ...
The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com. ...
Building upon SER-109, and in addition to SER-155, Seres is also evaluating additional preclinical stage programs in indications such as cancer neutropenia, solid organ transplant, and antimicrobial resistant infections more broadly. Ulcerative colitis (UC) research:The Company previously reported clinical, microbiome and metabolomic data from the SER-287 Phase 2b study and the ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). ...
Food and Drug Administration (FDA) Adverse Event Reporting System back to molecular pathways and target profile data, the two proof-of-concept studies examined potential causes of cardiotoxicity and of colitis associated with well-known targeted cancer therapies. Using this analytical method, the authors developed hypotheses about different molecular mechanisms that accentuate or ...
MB310 is a fully defined LBT comprising a consortium of bacteria for the treatment of Ulcerative Colitis (UC) identified as being linked to remission in a UC faecal transplant clinical study. ...
Proceeds from the Series A financing will allow completion of the development of the company’s first product for treating ulcerative colitis, readying it for human trials, and further the development of the overall technology platform. ...
Vedanta plans to move this consortium forward to a Phase 2 study in patients with ulcerative colitis. The study will be partially funded with the proceeds from a $25 million investment from Pfizer, as part of the Pfizer Breakthrough Growth Initiative, which was announced in January 2021. ...
IBD is a lifelong, chronic disease that affects the digestive system, and includes Crohn's disease and ulcerative colitis. Bouts can last for days, weeks or months at a time. By the end of this collaboration, CytoReason intends to present insights on the top drug targets in order to provide new therapeutic options for IBD patients. ...
Recent achievements include a key new strategic collaboration with Cancer Research UK and Cambridge University Hospitals, progressing lead programmes in ulcerative colitis and immuno-oncology towards the clinic, and moving into purpose-configured facilities at Chesterford Research Park. ...
Millions of people live with UC globally.2 "There is a continued need for additional treatments that can provide people living with ulcerative colitis relief from their most challenging symptoms," said William J. ...